Morán C, Tena G, Fonseca M E, Ochoa R, Bermúdez J A, Zárate A
Endocrine Research Unit, Hospital Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, México, D.F.
Arch Med Res. 1994 Spring;25(1):1-3.
Variations in serum molecular forms of prolactin (PRL) from an adolescent woman presenting amenorrhea-galactorrhea are reported. Persistent hyperprolactinemia and hypoestrogenism were demonstrated as well as the presence of a pituitary tumor with suprasellar extension. Bromocriptine was given at progressive doses up to 37 mg daily, decreasing the hyperprolactinemia and galactorrhea. After 2 years of treatment the patient noticed symptoms of gastric intolerance, bromocriptine was discontinued and a rebound of hyperprolactinemia was observed. Lisuride was administered instead resulting in a new decrease in PRL serum levels, disappearance of galactorrhea and beginning of regular menses. Serum gel chromatographic analysis was carried out before and during lisuride treatment. The first chromatographic analysis showed a predominance of high molecular weight (approximately 66 KD) PRL, accounting for more than 90% of the immunoreactive PRL. The second chromatography showed the major peak of immunoreactive PRL displaced to the right (molecular weight of 22 KD), which was eluted near the PRL standard. With these chromatographic patterns it is concluded that the pituitary macroprolactinoma secreted different molecular forms of PRL and treatment with lisuride appeared to exert some effect on the PRL molecular size secreted by the pituitary.
报告了一名患有闭经 - 溢乳的青春期女性血清催乳素（PRL）分子形式的变化。证实存在持续性高催乳素血症和低雌激素血症，以及伴有鞍上扩展的垂体肿瘤。给予溴隐亭，剂量逐渐增加至每日37毫克，高催乳素血症和溢乳症状减轻。治疗2年后，患者出现胃不耐受症状，停用溴隐亭后观察到高催乳素血症反弹。改用利舒脲治疗，导致PRL血清水平再次下降，溢乳消失且月经恢复正常。在利舒脲治疗前和治疗期间进行了血清凝胶色谱分析。首次色谱分析显示高分子量（约66 KD）PRL占主导，占免疫反应性PRL的90%以上。第二次色谱分析显示免疫反应性PRL的主峰向右移位（分子量为22 KD），在PRL标准品附近洗脱。根据这些色谱图谱得出结论，垂体大泌乳素瘤分泌不同分子形式的PRL，利舒脲治疗似乎对垂体分泌的PRL分子大小有一定影响。
